Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women.
A total of 104 postmenopausal women were randomly assigned to different therapeutic regimens: (a) calcitonin, (b) estrogen/progestogen (HRT) plus calcitonin, (c) estrogen/progestogen (HRT), (d) and the control group. The bone mass of the lumbar vertebrae of all patients was assessed with a dual beam photon absorptiometer (Norland GD 153). The 73 patients who completed the 1-yr study showed that postmenopausal bone loss could be prevented by either estrogen/progestogen (HRT) or calcitonin. In addition, the combination of hormonal replacement therapy and calcitonin not only prevented post-menopausal bone loss but resulted in a significant 10% gain in bone mass (P < 0.001).
Meschia
M
M
2nd Department of Obstetrics and Gynecology, University of Milan, Italy.
Brincat
M
M
Barbacini
P
P
Maini
M C
MC
Marri
R
R
Crosignani
P G
PG
D015502:Absorptiometry, Photon; D000704:Analysis of Variance; D015519:Bone Density / Q000187:drug effects*; D002116:Calcitonin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*
D004966:Estrogens, Conjugated (USP); D002116:Calcitonin; D017258:Medroxyprogesterone Acetate; C012755:elcatonin